ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

risankizumab

Also written as “Risankizumab”, “risankizumab IV” and “risankizumab SC”.

Its studies are mostly in Psoriasis · Crohn Disease · Arthritis, Psoriatic · Colitis, Ulcerative · Arthritis, Juvenile, led by 3 companies.

Drug pageRisankizumab: every studyAll 77 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 28, 202168 company-led studies, 16 open or runningNext primary completion: Jan 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVieits history only6515 open or runningphase 4since May 28, 2021Apr 10, 2012Jan 2027phase 1 · NCT07466550
Johnson & Johnson21 open or runningphase 3since Mar 23, 2026Oct 11, 2021Nov 15, 2028phase 3 · NCT07499232
Boehringer Ingelheimits history only10 open or runningphase 2since Feb 3, 2014Feb 3, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named risankizumabINNProposed as its International Nonproprietary Name in WHO's List 113 · before, BI 655066
  2. Oct 11, 2021First study: phase 1 study in Arthritis, PsoriaticFirst studyNCT05083078 · 11 enrolled · Austria
  3. Mar 23, 2026Phase 3 study in Crohn DiseasePhase 3 reachedNCT07499232 · 530 planned · United States, Austria, Belgium and more

Ahead

  1. Nov 15, 2028Primary completion: phase 3 study in Crohn DiseaseNCT07499232

TargetBeta

IL12B →IL23A →read by rule
“Interleukin-23 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
guselkumabruleJohnson & Johnsonphase 460
mirikizumabruleEli Lillyphase 436

Studies

All 2 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07499232Crohn Disease · United States, Austria, Belgium and more3RecruitingNov 15, 2028530
NCT05083078Arthritis, Psoriatic · Austria1TerminatedJul 1, 202211

How it is read

Names in the registry

  • “Risankizumab”, 53 entries
  • “risankizumab”, 17 entries
  • “risankizumab IV”, 4 entries
  • “risankizumab SC”, 4 entries
  • “BI 655066”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.